Hepatotoxicity of Clozapine

Authors:
  • MKMartin Kurz
    Martin Kurz
  • IKIlsemarie Kurzthaler
    Ilsemarie Kurzthaler
  • HOHarald Oberbauer
    Harald Oberbauer
  • CMCarl Miller
    Carl Miller
  • WFW. Wolfgang Fleischhacker
    W. Wolfgang Fleischhacker

Abstract
Two hundred thirty-eight patients treated with either haloperidol or clozapine were investigated to shed more light on the incidence and severity of antipsychotic-induced liver enzyme increase. Serum glutamic-pyruvic transaminase (SGPT) increase was most frequently seen in both treatment groups. When analyzing the incidence rates for patients with increased liver enzyme values (serum glutamic-oxaloacetic transaminase, SGPT, gamma-glutamyl transpeptidase) that were higher than twice the upper limit of the normal range, clozapine-treated patients showed an SGPT increase (37.3%) significantly more frequently than patients treated with haloperidol (16.6%). Both patients with higher clozapine plasma levels and male patients were at a higher risk for an SGPT increase. At least 60% of the increase of the different enzymes remitted within the first 13 weeks of treatment. In general, the authors conclude that clozapine-induced liver enzyme elevation seems to be a common and mostly transient phenomenon. (J Clin Psychopharmacol 1997;17:314-317).

This publication has 12 references indexed in Scilit: